Table 4.
Proportion of participants with solicited adverse events within 7 days after vaccination
|
Vi-DT vaccine group |
Vi-TT vaccine group | Vi-DT vaccine lot 1 plus lot 2 plus lot 3 vs Vi-TT vaccine p value* | Vi-DT vaccine lot 1 vs lot 2 vs lot 3 vs Vi-TT vaccine p value* | ||||
|---|---|---|---|---|---|---|---|
| All lots | Lot 1 | Lot 2 | Lot 3 | ||||
| All ages | 260/1350 (19·3%; 17·2–21·5) | 81/450 (18·0%; 14·7–21·8) | 91/450 (20·2%; 16·8–24·2) | 88/450 (19·6%; 16·2–23·5) | 115/450 (25·6%; 21·7–29·8) | 0·0044 | 0·032 |
| Age 6 months to <2 years | 97/450 (21·6%; 18·0–25·6) | 31/150 (20·7%;15·0–27·8 | 29/150 (19·3%; 13·8–26·4) | 37/150 (24·7%; 18·5–32·1) | 42/150 (28·0%; 21·4–35·7) | 0·11 | 0·27 |
| Age 2 years to <18 years | 70/450 (15·6%; 12·5–19·2) | 23/150 (15·3%; 10·4–22·0) | 28/150 (18·7%; 13·2–25·7) | 19/150 (12·7%; 8·3–18·9) | 34/150 (22·7%; 16·7–30·0) | 0·046 | 0·12 |
| Age 18 years to 45 years | 93/450 (20·7%; 17·2–24·7) | 27/150 (18·0%; 12·7–24·9) | 34/150 (22·7%; 16·7–30·0) | 32/150 (21·3%; 15·5–28·6) | 39/150 (26·0%; 19·6–33·6) | 0·17 | 0·41 |
Data are n/N (%; 95% CI), unless otherwise indicated. n=number of participants who reported events. N=total number of participants. Vi-DT=Vi polysaccharide-diphtheria toxoid. Vi-TT=Vi polysaccharide-tetanus toxoid.
*
p values were calculated by use of χ2 tests.